BSI response to UK Government's Comprehensive Spending Review

Professor Peter Openshaw, President of the British Society for Immunology, said:
“The British Society for Immunology welcomes the announcement by the UK Government in today’s Comprehensive Spending review that the science budget will be protected in real terms, and that there will be extra money for the NHS. The UK’s ability to conduct high-quality, cutting edge fundamental research is a critical factor in our ability to understand the science behind immunological and infectious disease and to find new approaches to prevention and treatment of these important and sometimes devastating conditions. Science and innovation are key factors in growing this country’s economy and contributing to our national successes. Good science costs money, but is well worth the investment. 
“We are also pleased to see investment in genomics, antimicrobial resistance research and the establishment of the £1bn Ross Fund to invest in drugs, vaccines, diagnostics and treatments to combat infectious disease worldwide in partnership with the Bill and Melinda Gates Foundation, as well as the announcement of the £1.5m Global Challenges Fund to tackle problems faced by developing countries. 
“However, we are concerned that the proposed cuts and changes to the public health budget may impact on the preventative and surveillance services that underpin the UK’s excellent vaccine programmes.  Public health plays a critical role in preventing disease, preserving good health and saving a great deal of expense in treating preventable disease.  George Osborne said that his aim was to “develop a modern, integrated, health and social care system that supports people at every stage of their lives”.  Public health has to be a vital part of this strategy, and a decrease spend on this aspect will undoubtedly cost the NHS more in the long term.
“There still are important details to come out, particularly with respect to changes in the Research Excellence Framework and the implications of the Comprehensive Spending Review for our universities. We will be analysing this and subsequent statements carefully.”

Mid-career blues, mid-career changes

New this month on the BSI blog (, Peter Openshaw, President of the BSI, discusses the challenges relating to career structure that researchers can face as they progress through their careers and what the BSI can do to support them.  You can read the blog here
Do add your comments and thoughts on what support you would like from the BSI.  Image credit: Shutterstock.

Clinical & Experimental Immunology (CEI)

& Experimental Immunology (CEI) are seeking a new Editor in Chief to join the journal from September 2016. CEI is a high-ranking, internationally respected journal publishing impactful clinical and translational immunology research papers and reviews. The successful candidate will work closely with the BSI editorial team to drive the editorial direction and development of this high ranking monthly journal.

For further information and job description please click here

Highlight from the journals: Innate mucosal-associated invariant T cells are activated in inflammatory bowel diseases

MAIT Cells
Inflammatory bowel diseases are characterized by a deregulated immune response targeting the gut bacterial flora. Mucosal-associated invariant T (MAIT) cells are major histocompatibility complex (MHC) class Ib-restricted innate-like lymphocytes with anti-bacterial functions. They display an effector/memory phenotype and are found in large numbers in the blood, mucosae and liver. They have also been implicated in inflammatory diseases such as multiple sclerosis.

In their research article from Clinical and Experimental Immunology, Serriari, Treiner et al show that MAIT cells are activated in IBD, which results in an increased recruitment towards the inflamed tissues, an altered phenotype and a switch in the pattern of cytokine secretion. Read the article.

Rheumatology 2016

We're delighted to announce the that the BSI and the British Society for Rheumatology (BSR) are conducting a joint session during Rheumatology 2016.

The meeting is due to take place at the Scottish Exhibition and Conference Centre in Glasgow from 26-28 April 2016.

To submit an abstract, please click here and submit before the 06 November deadline.  

The British Society for Immunology (BSI) actively promotes and supports excellence in research, scholarship and clinical practice in Immunology for the benefit of human and animal health and welfare. It seeks to help British Immunology accomplish the highest possible goals.

The BSI is a member of:
    Royal Society of Biology     Federation of Clinical Immunology Societies  
    Transplant 2020  

Search the BSI

Members login








BSI Twitter